MedPath

Fetal Growth Restriction: Management Using Two Guidelines - Fetal Growth Antenatal Management Evaluation

Not Applicable
Not yet recruiting
Conditions
Fetal Growth Retardation
Interventions
Other: Ultrasound following the SMFM guidelines
Other: Ultrasound following the ISUOG guidelines
Registration Number
NCT05938829
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

The purpose of this study is to compare the composite neonatal adverse outcomes (CNAO) among pregnancies complicated by fetal growth restriction (FGR) managed using the Society of Maternal-Fetal Medicine (SMFM) versus International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) antepartum ultrasound guidelines, to measure the rate of the individual components of CNAO, to record the rate of cesarean delivery during labor, to tabulate the rate of deviation from the management protocol assigned at the time of evaluation, to record neonatal intensive care unit (NICU) admission rates and to measure the rate of the composite maternal adverse outcome (CMAO).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1100
Inclusion Criteria
  • FGR diagnosed during sonographic examinations
  • estimated fetal weight less than or a fetal abdominal circumference less than the 10th percentile
Exclusion Criteria
  • Multiple gestations with FGR

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Ultrasound using SMFM guidelines, then ultrasound using ISUOG guidelinesUltrasound following the SMFM guidelinesEach site will utilize SMFM guidelines for the first 12 months and then there will be a 2 week washout period, after which each site will utilize ISUOG guidelines for 12 months
Ultrasound using SMFM guidelines, then ultrasound using ISUOG guidelinesUltrasound following the ISUOG guidelinesEach site will utilize SMFM guidelines for the first 12 months and then there will be a 2 week washout period, after which each site will utilize ISUOG guidelines for 12 months
Primary Outcome Measures
NameTimeMethod
Number of neonates who have composite neonatal adverse outcomes (CNAO)from time of birth to 30 days after birth
Secondary Outcome Measures
NameTimeMethod
Number of participants that need mechanical ventilation6 hours after birth
Number of cesarean deliveriesat the time of delivery
Number of participants that are admitted to neonatal intensive care unit (NICU)from time of birth to 30 days after birth
Number of participants for whom there was a deviation from the management protocolfrom time of diagnosis of fetal growth restriction to delivery
Number of mothers who have composite maternal adverse outcomes (CMAO)from time of birth to 30 days after birth

This includes estimated blood loss (EBL) / quantitative blood loss (QBL) \> 1,000 mL, Transfusion, chorioamnionitis, ICU admission, or Maternal death

Number of participants with Apgar score < 7at 5 minutes after birth
Number of participants that have culture-proven neonatal sepsisfrom time of birth to 30 days after birth
Number of participants that are still born or show neonatal deathfrom time of birth to 30 days after birth
Number of participants that show signs of neonatal seizurefrom time of birth to 30 days after birth
Number of participants that have intracranial hemorrhagefrom time of birth to 30 days after birth

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath